NIKKEI 225
39,687.40 +104.32 (+0.26%) HANG SENG
17,718.61 +2.11 (+0.01%) CRUDE OIL
81.96 +0.42 (+0.52%) GOLD FUTURES
2,336.00 -3.60 (-0.15%) DOW
39,118.86 -45.24 (-0.12%) Bitcoin GBP
50,019.85 +1,966.89 (+4.09%)
SAVA Jan 2026 2.500 call
| Previous close | 26.70 |
| Open | 9.50 |
| Bid | 8.00 |
| Ask | 13.00 |
| Strike | 2.50 |
| Expiry date | 2026-01-16 |
| Day's range | 9.50 - 10.53 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Barrons.comCassava Sciences Shares Plunge on Indictment Against Former Advisor
A federal indictment accuses a Cassava Sciences advisor of faking data to secure NIH grants. The company also faces shareholder suits.
GlobeNewswireCassava Sciences Issues Statement on Former Science Advisor
AUSTIN, Texas, June 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), reported it has learned today that a federal grand jury returned an indictment charging Hoau-Yan Wang for allegedly defrauding the U.S. National Institutes of Health (NIH). Hoau-Yan Wang was a tenured medical professor at a public university’s medical school as well as a former paid science advisor to Cassava Sciences. According to public court documents, Dr. Wang engaged in illegal behavior to defraud the go
ZacksCassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
